Leonard Lev, MD
Psychiatry · Rehoboth Beach, DENPI 1033287982
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 87 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 38.0% of the total. 2025 is the largest year on record at $660, 2.5 times the $267 reported in 2019.
Across 87 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$711
- Otsuka America Pharmaceutical, Inc.$289
- Neurocrine Biosciences, Inc.$178
- Alkermes, Inc.$167
- Indivior Inc.$123
- Johnson & Johnson$120
- plus $286 from 6 others
What the payments were for
- Food & beverage$1,86099%
- Education$131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 29 | $711 |
| Otsuka America Pharmaceutical, Inc. | 8 | $289 |
| Neurocrine Biosciences, Inc. | 33 | $178 |
| Alkermes, Inc. | 4 | $167 |
| Indivior Inc. | 1 | $123 |
| Johnson & Johnson | 1 | $120 |
| Axsome Therapeutics, Inc. | 3 | $107 |
| Lundbeck LLC | 4 | $81 |
| Brainsway USA Inc | 1 | $50 |
| Novo Nordisk | 1 | $18 |
| Orexo US, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$480
- VRAYLAR$245
- REXULTI$124
- SUBLOCADE$123
- INVEGA SUSTENNA$120
- INVEGA TRINZA$120
- ARISTADA INITIO$120
How this compares
$1,873 in reported general payments places this provider in the 85th percentile of 114 psychiatry providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 49 | $75,984 |
| TrintellixVortioxetine Hydrobromide | 18 | $16,484 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 31 | $5,660 |
| Bupropion XlBupropion Hcl | 190 | $5,161 |
| Aripiprazole | 105 | $4,378 |
| Duloxetine Hcl | 102 | $4,314 |
| Escitalopram Oxalate | 335 | $4,169 |
| Quetiapine Fumarate | 191 | $3,927 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 127 | $3,825 |
| Mirtazapine | 122 | $3,207 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 46 | $3,037 |
| Bupropion Hcl SrBupropion Hcl | 139 | $2,622 |
| Desipramine Hcl | 15 | $2,240 |
| Buspirone Hcl | 135 | $2,201 |
| Doxepin Hcl | 90 | $2,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $289 | $75,98449 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 114 psychiatry providers in Delaware.
Other psychiatry in Rehoboth Beach
- Duane ShubertRehoboth Beach$463
- Ranganathan RamWilmington$202K
- Manisha WadhwaWilmington$89K
- Vishesh AgarwalWilmington$46K
- Anis AhmedMillsboro$8K
- Dilipkumar JoshiNewark$6K
- Andrew PittsLewes$5K
- Jeet JoshiNewark$5K
- Kathlyn RowenWilmington$5K
- Alexander JacobsonNewark$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.